

# Fbxw7 regulates hepatocellular carcinoma migration and invasion via Notch1 signaling pathway

XING WANG<sup>1\*</sup>, JUAN ZHANG<sup>2\*</sup>, LIANG ZHOU<sup>3\*</sup>, WEI SUN<sup>1\*</sup>, ZHI-GANG ZHENG<sup>1</sup>, PENG LU<sup>1</sup>, YUAN GAO<sup>1</sup>, XI-SHENG YANG<sup>1</sup>, ZHUO-CHAO ZHANG<sup>1</sup>, KAI-SHAN TAO<sup>1</sup> and KE-FENG DOU<sup>1</sup>

<sup>1</sup>Department of Hepatobiliary Surgery, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shannxi 710032;

<sup>2</sup>Department of ENT, The 44 Central Hospital of PLA, Guiyang, Guizhou 550009; <sup>3</sup>Department of General Surgery, The 155 Central Hospital of PLA, Kaifeng, Henan 471000, P.R. China

Received February 18, 2015; Accepted April 9, 2015

DOI: 10.3892/ijo.2015.2981

**Abstract.** Hepatocellular carcinoma (HCC) is one of the most common human malignancies and also the leading cause of cancer-related death in the world. The mechanisms underlying the progression and metastasis of HCC remain unclear. The E3 ubiquitin ligase F-box and WD repeat domain-containing 7 (Fbxw7) is broadly considered as a tumor suppressor gene. However, the role of Fbxw7 in HCC is not clear. To investigate the expression and biological functions of Fbxw7 in HCC, we examined Fbxw7 expression level using HCC tissue microarray and immunohistochemistry. Our data showed that Fbxw7 expression is significantly reduced in HCC compared with non-cancerous tissues ( $P < 0.05$ ). Fbxw7 levels were significantly associated with tumor differentiation ( $P = 0.013$ ), the incidence of portal or hepatic venous invasion ( $P = 0.031$ ), metastasis ( $P = 0.027$ ) and AJCC cancer stage ( $P = 0.047$ ). Then, we observed a strong correlation between low Fbxw7 expression and a worse 5-year survival of HCC patients ( $P < 0.001$ ). Furthermore, multivariate Cox regression analyses demonstrated that the Fbxw7 expression ( $P < 0.001$ ) was an independent factor for the prediction of the overall survival of HCC patients. We also found that both Fbxw7 mRNA and protein levels were significantly reduced in HCC cell lines compared with human liver non-tumor cell line. Moreover, our *in vitro* experiments showed a remarkable increase of cell migration and invasion in Fbxw7-knockdown cells and a decrease in Fbxw7-overexpress cells. In addition, the present

study demonstrated that Fbxw7 is involved in the migration and invasion of HCC cells via regulating Notch1 and the downstream molecules of Notch1. Taken together, our findings indicate that Fbxw7 can be used as a prognostic marker; it has an important role in HCC progression and inhibits HCC cell migration and invasion through the Notch1 signaling pathway.

## Introduction

With the improvement of the systemic chemotherapy, the popularity of liver transplantation, even the rapid progress of liver xenotransplantation, today, however, the prognosis of patients with hepatocellular carcinoma (HCC) is still not optimistic. Because of the initially asymptomatic development and unpredictable tumor metastasis of HCC, most patients have a limited number of therapeutic options at the time of diagnosis (1,2). Moreover, the recurrence of tumor after surgery greatly reduces the survival rate of HCC patients. Most crucially, the mechanisms underlying the HCC progression remain unclear.

Fbxw7 (F-box and WD repeat domain containing 7, also known as Fbw7, hCdc4, hAgo, or SEL-10) is an F-box protein belonging to the SCF (SKP1-CUL1-F-box protein) E3 ligase complex. Fbxw7 is responsible for transferring the ubiquitin molecule to the substrate, resulting in its recognition and degradation (3). Fbxw7 has been characterized as a general tumor suppressor in human cancer and plays a critical role in the cell cycle, proliferation, differentiation, apoptosis, tumor metastasis and drug resistance (4,5). Studies have showed several specific substrates of Fbxw7 including cyclin E, c-Myc, Notch-1, SREBP1 (sterol regulatory element binding protein-1), c-Jun, mTOR (mammalian target of rapamycin) and MCL-1 (myeloid cell leukemia-1) (6-13). Related to oncology clinical and basic research, the reduced expression or loss-of-function mutations of Fbxw7 have been frequently found in various human cancers, and overall mutation frequency was ~6% (14). Mutations of Fbxw7 have been detected in many types of human malignancy, including T cell acute lymphoblastic leukemia, pancreatic, gastric, colorectal, prostate, cholangiocarcinoma and endometrial cancer (15-20). In addition, multiple studies demonstrated that Fbxw7 may have functions in tumor migration and metastasis such as gastric cancer and melanoma (21,22). Until very recently, two small

*Correspondence to:* Professor Ke-Feng Dou or Professor Kai-Shan Tao, Department of Hepatobiliary Surgery, Xijing Hospital, The Fourth Military Medical University, Changlexi Road, Xi'an, Shannxi 710032, P.R. China

E-mail: doukf\_fmму@foxmail.com

E-mail: taoks\_fmму@foxmail.com

\*Contributed equally

**Key words:** hepatocellular carcinoma, Fbxw7, Notch1, migration, invasion

clinical sample studies have reported where reduced Fbxw7 expression correlated with clinicopathological characteristics and may have an independent prognostic factor for tumor recurrence in HCC (23,24). However, the relationship between Fbxw7 and HCC invasion and metastasis, and its exact function in HCC cells migration and invasion are unknown.

Relevant reports indicate that Notch1 is involved in tumor cell invasion in pancreatic, breast cancer, lingual squamous cell carcinoma and HCC (25-28). Previous studies in our laboratory showed that downregulation of Notch1 decreased the migration and invasion capacities of HCC cells via the COX-2 and ERK1/2 pathways (29). Latest studies proved that Notch1, as the substrate of Fbxw7, which can inhibit melanoma cell migration, was activated to promote melanoma angiogenesis and tumor growth through Fbxw7 silencing (22,30). However, whether Fbxw7/Notch1 axis participates in the process of metastasis and invasion in HCC remains unclear.

We established the present study to investigate the role of Fbxw7/Notch1 in HCC cells migration and invasion. First, we used tissue microarray (TMA) and immunohistochemistry to examine the expression of Fbxw7 protein in the HCC tissues compared with non-cancerous tissues. Then, we explored the potential mechanism of Fbxw7/Notch1 involvement in the migration and invasion of HCC cells *in vitro*.

## Materials and methods

**Patients.** HCC tissue and adjacent non-cancerous hepatic tissues (at least 1.5 cm away from the tumor) were collected from 102 patients suffering from primary hepatocellular carcinoma between 2006 and 2009. All subjects were admitted to and received surgical resection in the Department of Hepatobiliary Surgery, Xijing Hospital, the Fourth Military Medical University Hospital, Xian, China. The patients did not receive treatment using any drug, hepatic artery embolization, or percutaneous ethanol injection prior to surgical resection to exclude patients with other cancers or with accompanying serious infections. There were 66 male and 36 female patients, with a median age of 46.4 years (range, 26-76 years). The Ethics Committee of the Fourth Military Medical University approved the study protocol. All the participants were fully informed the research study details, and the participants or legal guardians of the participants signed written informed consent before the inclusion in the study. Clinical parameters, such as gender, age, liver cirrhosis, tumor number, tumor size, tumor differentiation, AFP, metastasis and American Joint Committee on Cancer (AJCC) staging were collected. In the patients diagnosed with metastasis, we also analyzed venous invasion. Among the 31 cases diagnosed with metastasis, complications included venous invasion (n=24), bile duct tumor thrombi (n=13) and lymph node metastasis were verified by pathological analysis (n=5). All patients enrolled were followed for 5 years for survival calculations.

**Immunohistochemistry and evaluation of staining.** Formaldehyde-fixed and paraffin-embedded sections of all tissues were subjected to immunohistochemistry and stained with antibodies against Fbxw7 using the avidin-biotin-peroxidase complex method. All sections were deparaffinized in xylene and dehydrated through a graduated alcohol series

before endogenous peroxidase activity was blocked with 0.5% H<sub>2</sub>O<sub>2</sub> in methanol for 10 min. Non-specific binding was blocked by incubating sections with 10% normal goat serum in PBS for 1 h at room temperature. The sections were incubated with anti-Fbxw7 (1:150, TA802869, from OriGene Technologies, Inc., Rockville, MD, USA) in PBS at 4°C overnight in a moist chamber. The sections were incubated with biotinylated IgG for 2 h at room temperature and detected with a streptavidin-peroxidase complex. The brown color indicative of peroxidase activity was obtained by incubating the section with 0.1% 3,3-diaminobenzidine (DAB) in PBS with 0.03% H<sub>2</sub>O<sub>2</sub> for 10 min at room temperature. Fbxw7 expression in tissues were evaluated by scanning the entire specimen under low magnification (x100) and then confirmed under high magnification (x400). The tissue specimens were scored independently by two pathologists using an immunoreactivity score system described by Barnes *et al.* (31). Based on the score, we divided all HCC specimens into two subgroups: the low expression group (score of 0-3) and high expression group (score of 4-12).

**Cell lines and cell culture.** The human liver non-tumor cell line HL-7702 and HCC cell lines HepG2, SMMC-7721 and MHCC97H were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Cells were routinely cultivated in Dulbecco's modified Eagle's medium (DMEM; HyClone, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS; Invitrogen, Carlsbad, CA, USA) in a humidified incubator containing 5% CO<sub>2</sub> at 37°C.

**RNA extraction and quantitative RT-PCR.** Total RNA was isolated from cells using TRIzol reagent (Invitrogen) following the manufacturer's instructions. The concentration of RNA was determined by measuring the absorbance at 260 nm (A<sub>260</sub>) in an Ultrospec 1100 spectrophotometer (GE Healthcare, Princeton, NJ, USA). For mRNA analysis, complementary DNA (cDNA) was generated with oligo-dT primers using the PrimeScript RT reagent kit (Takara, Dalian, China). Amplification of the generated cDNA was performed using SYBR Premix EX Taq II (Takara) on IQ5 detection system (Bio-Rad Laboratories, Hercules, CA, USA). The human housekeeping gene GAPDH was used as an internal control to normalize mRNA expression levels of target genes. All of the above experiments were performed according to the manufacturer's instructions.

Real-time PCR was performed using an IQ5 real-time PCR detection system. The relative expression of each mRNA was calculated using the comparative cycle threshold (CT) method (2<sup>-ΔΔCT</sup>). The qPCR primers (listed in Table I) were designed and synthesized by Shanghai Sangon Biotechnology Co., Ltd. (Shanghai, China).

**Vector construction and lentivirus infection.** In order to upregulate the expression of Fbxw7 in HCC cells, the Fbxw7 (NM\_033632) ORF was amplified using the primer 5'-CCA ACTTTGTGCCAACCGGTCGCCACCATGAATCAGGA CATGCTCTC-3' and 5'-AATGCCAACTCTGAGCTTCTT CATGTCCACATCAAAGTC-3' with the introduction of restriction endonuclease *Age*I site. Fbxw7 cDNA digested with *Age*I was cloned into an *Age*I-digested pGC-FU-3FLAG-SV40-GFP vector (Shanghai GeneChem Co., Ltd., Shanghai,

Table I. Sequences of qRT-PCR primers used for mRNA analysis.

mRNA	Sequences
Fbxw7	Forward: 5'-GTCCCGAGAAGCGGTTTGATA-3' Reverse: 5'-TGCTCAGGCACGTCAGAAAAG-3'
Notch1	Forward: 5'-CACCCATGACCACTACCCAGTT-3' Reverse: 5'-CCTCGGACCAATCAGAGATGTT-3'
GAPDH	Forward: 5'-TGACTTCAACAGCGACACCCA-3' Reverse: 5'-CACCTGTTGCTGTAGCCAAA-3'

China). The resulting lentivirus vector together with pHelper1 and pHelper2 vectors were co-transfected into 293FT cells for 48 h using lipofectamine 2000 (Invitrogen) to generate lentiviral stock. An 'empty' vector pGC-FU-3FLAG-SV40-GFP was utilized as a negative control (NC). After the titers were determined, the lentiviral particles were used to infect MHCC97H cells (OE-Fbxw7-97H).

In order to downregulate the expression of Fbxw7 in HepG2 cells, on the basis of GenBank information for Fbxw7, the sequences for shRNAs targeting the Fbxw7 gene are as follows: Fbxw7-KD: 5'-TAAAGAGTTGGCACTCTAT-3'. Oligonucleotides were cloned into the lentiviral vector pGCSIL-GFP (GeneChem), and named as KD-Fbxw7-HepG2. Sequence not related to Fbxw7 sequence with mismatched bases was designed (5'-TTCTCCGAACGTGTACGT-3'), used as negative control (KD-NC). All lentivirus-mediated upregulating/downregulating of Fbxw7 were verified by qRT-PCR and western blot analysis.

**MTT assay.** Treated cells were seeded into 96-well cell culture plates at a density of  $1 \times 10^4$  cells/well and were grown for up to 48 h. Cell viability was assessed using the 3-(4,5-dimethyl-2-thiazyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay (Sigma Chemicals) following the manufacturer's protocols. Each experiment included six replications and was repeated three times. The data are summarized as the means  $\pm$  SDs.

**Transwell cell migration/invasion assay.** The migration and invasion ability of the cells was assessed using uncoated or Matrigel-coated Transwell cell culture chambers (8  $\mu$ m pore size; Millipore, Billerica, MA, USA). Briefly, 600  $\mu$ l medium containing 10% FBS as a chemo-attractant was added to the lower 24-well chamber. Treated cells were resuspended in serum-free medium, and then 200  $\mu$ l of the single-cell suspension ( $2 \times 10^4$  cells) was seeded onto the upper chamber of each Transwell. After incubation for 24 h, cells on the upper side of the filters were mechanically removed using a cotton swab, after which the membrane was fixed with 4% formaldehyde for 10 min at room temperature, and stained with 0.05% crystal violet for 10 min. Finally, invasive cells were counted at  $\times 200$  magnification from five randomly selected areas per well. Each experiment was performed in triplicate.

**Small interfering RNA transfection.** For Notch1 inhibition studies, transient transfection of lentivirus-treated HCC

cells with small-interfering RNA (siRNA) targeting Notch1 mRNA (siNotch1) or control siRNA (siControl; Santa Cruz Biotechnology, Santa Cruz, CA, USA) was performed. Briefly,  $1 \times 10^5$  lentivirus-treated cells were plated per well in 6-well plates in media containing 10% FBS to achieve 50% confluence, and then transfection of siNotch1 or siControl was performed using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. The cells were allowed to grow for an additional 48 h and were then harvested for further analysis.

**Protein extraction and western blotting.** Cells were washed three times with ice-cold phosphate-buffered saline (PBS) and lysed with lysis buffer (P0013B; Beyotime Institute of Biotechnology, Shanghai, China) containing 1 mmol/l PMSF and incubated on ice for 20 min. The lysates were then centrifuged at 12,000 rpm at 4°C for 25 min. Aliquots of the supernatant were denatured in boiling water for 5 min and quantified for the next analysis. The protein concentrations were determined using the Bio-Rad assay system (Bio-Rad Laboratories). Total proteins were concentrated and separated using 10% sodium dodecyl sulfate-polyacrylamide (SDS-PAGE) gel electrophoresis and transferred to polyvinylidene difluoride (PVDF) membranes (Millipore). The membranes were blocked with 5% non-fat dried milk in 1X TBST, and were then incubated with primary antibodies against Primary antibodies for the Notch1 intracellular domain (Abcam, Cambridge, UK), Notch1, MMP-2, MMP-9 and uPA (Santa Cruz Biotechnology) overnight at 4°C. Horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (1:5,000; Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd., Beijing, China) was used as the secondary antibody, and the protein bands were visualized using the ChemiDoc™ XRS+ system with Image Lab™ software (Bio-Rad Laboratories). The western blots were quantified using laser densitometry, and the relative protein expression was normalized to  $\beta$ -actin (#4970; Cell Signaling Technology).

**Statistical analysis.** HCC staging was determined according to the AJCC TNM staging system (7th edition). Statistical analyses were performed using SPSS statistics version 17.0 software (IBM, Chicago, IL, USA). All figures were generated using GraphPad Prism 5.01 (GraphPad Software, La Jolla, CA, USA). All experiments were repeated at least three times, and the data are summarized and presented as means  $\pm$  SDs. The differences between means were analyzed statistically using t-tests. The differences between two groups of Fbxw7 with various clinicopathological factors were assessed using  $\chi^2$  tests. Survival curves were calculated using the Kaplan-Meier method and compared with the log-rank test. The Cox proportional hazard analysis was employed for univariate and multivariate analyses to assess the effect of clinicopathological factors and Fbxw7 on survival. A P-value  $< 0.05$  denotes the presence of a statistically significant difference.

## Results

**Immunohistochemical analyses of Fbxw7.** To observe the clinical significance of Fbxw7 in HCC, the expression of Fbxw7 protein was analyzed by immunostaining in 102 pairs




Figure 1. Expression of Fbxw7 in HCC tissues. (A-D) Fbxw7 expression in HCC tissues: (A) negative, (B) weakly positive, (C) moderately positive and (D) strongly positive. Original magnification, x100.

of cancerous and matched non-cancerous tissue samples from HCC patients introduced above. Fbxw7 was mainly localized in the cytoplasm and nucleus. As Fig. 1 shows, the expression of Fbxw7 was different in HCC tissues. The expression of Fbxw7 was evaluated using a subjective composite score which were multiplied together by the intensity and proportion of cells staining. The proportion of cells staining positively was scored as 0, negative; 1, 1-25%; 2, 26-50%; 3, 51-75%, 4, >75%; and the staining intensity was scored as 0, negative; 1, weak; 2, moderate; 3, strong. In the present study, Fbxw7 immunoreactivity was considered as either relatively low expression group (score of 0-3) or relatively high expression group (score of 4-12). In the 102 cases, Fbxw7 staining was detected in 79 samples (77.5%) of the non-cancerous tissues, whereas only 65 samples (63.7%) of the HCC tissues showed a positive Fbxw7 signal ( $P < 0.05$ ). Among the 23 non-cancerous samples without Fbxw7, there was no Fbxw7 staining either in 19 matched HCC tissues. In addition, Fbxw7 staining was not detected in further 18 samples of HCC tissues. Thus, weak positive staining of Fbxw7 was detected in 22 samples of HCC, moderate positive staining in 34 samples, and strong positive staining in 9 samples.

*Relationship between Fbxw7 expression and clinicopathological characteristics.* To determine the relationship between

Fbxw7 levels and the clinical data of HCC patients, 102 HCC patients were separated into relatively low expression group (score of 0-3, 59 cases) and relatively high expression group (score of 4-12, 43 cases). Their clinicopathological factors, including gender, age, the incidence of liver cirrhosis, tumor number, tumor size, degree of differentiation, the AFP levels, the incidence of portal or hepatic venous invasion, metastasis, and AJCC cancer stage were then summarized and compared (Table II). Data revealed that Fbxw7 levels were significantly associated with tumor differentiation ( $P = 0.013$ ), the incidence of portal or hepatic venous invasion ( $P = 0.031$ ), metastasis ( $P = 0.027$ ) and AJCC cancer stage ( $P = 0.047$ ). This suggests that Fbxw7 might be associated with HCC differentiation, invasion and metastasis.

*Strong Fbxw7 staining correlates with a better 5-year survival of HCC patient.* Because of the association between Fbxw7 expression and tumor differentiation, portal or hepatic venous invasion, metastasis and tumor staging, we next used Kaplan-Meier survival analysis to compare the postoperative survival curves of the two groups of HCC patients. The log-rank test demonstrated a significant difference in the postoperative survival between HCC patients with low and high levels of Fbxw7 expression ( $P < 0.001$ ) (Fig. 2). Patients with low Fbxw7 expression had a significantly decreased postoperative survival

Table II. Association of Fbxw7 expression with clinicopathological factors of 102 HCC patients.

Characteristics	N	Fbxw7 level		P-value	$\chi^2$
		Low score of 0-3	High score of 4-12		
All cases	102	59 (57.8)	43 (42.2)		
Gender					
Male	66	38 (57.6)	28 (42.4)	0.941	0.005
Female	36	21 (58.3)	15 (41.7)		
Age (years)					
$\geq 50$	45	26 (57.8)	19 (42.2)	0.991	0.000
$< 50$	57	33 (57.9)	24 (42.1)		
Liver cirrhosis					
Presence	42	28 (66.7)	14 (33.3)	0.131	2.280
Absence	60	31 (51.7)	29 (48.3)		
Tumor number					
Single	59	30 (50.8)	29 (49.2)	0.094	2.809
Multiple	43	29 (67.4)	14 (32.6)		
Tumor size (cm)					
$> 5$	50	29 (58.0)	21 (42.0)	0.975	0.001
$\leq 5$	52	30 (57.7)	22 (42.3)		
Differentiation					
High	59	28 (47.5)	31 (52.5)	0.013 <sup>a</sup>	6.190
Low	43	31 (72.1)	12 (27.9)		
AFP					
$\geq 400$	55	33 (60.0)	22 (40.0)	0.633	0.228
$< 400$	47	26 (55.3)	21 (44.7)		
Venous invasion					
Yes	28	21 (75.0)	7 (25.0)	0.031 <sup>a</sup>	4.659
No	74	38 (51.4)	36 (48.6)		
Metastasis					
Yes	31	23 (74.2)	8 (25.8)	0.027 <sup>a</sup>	4.882
No	71	36 (50.7)	35 (49.3)		
AJCC staging					
I + II	34	15 (44.1)	19 (55.9)	0.047 <sup>a</sup>	3.940
III + IV	68	44 (64.7)	24 (35.3)		

<sup>a</sup>Statistically significant difference.

time. Patients with high Fbxw7 expression had a 24.2% 5-year survival rate; whereas those with low expression had a 9.5% 5-year survival rate.

To assess the prognostic value of Fbxw7 we first performed univariate Cox regression analysis, which revealed that the Fbxw7 expression ( $P < 0.001$ ), the degree of differentiation ( $P = 0.024$ ), venous invasion ( $P = 0.007$ ), metastasis ( $P < 0.001$ ) and AJCC staging ( $P = 0.018$ ) were significantly associated with overall survival of HCC patients (Table III). Furthermore, to evaluate the potential of low Fbxw7 expression as an independent predictor for overall survival of HCC, multivariate




Figure 2. Kaplan-Meier statistical analysis of postoperative survival curves in 102 HCC patients according to Fbxw7 expression levels ( $P < 0.001$ , log-rank test).

Cox regression analyses were performed. The analysis demonstrated that the Fbxw7 expression ( $P < 0.001$ ), the degree of differentiation ( $P = 0.012$ ), venous invasion ( $P = 0.015$ ), metastasis ( $P < 0.001$ ), and AJCC cancer staging ( $P < 0.001$ ) were independent factors for the prediction of the overall survival of HCC patients (Table III).

*The expression of Fbxw7 is reduced in HCC cell lines.* Clinical data analysis revealed that low expression of Fbxw7 was highly correlated with venous invasion ( $P = 0.031$ ) and metastasis ( $P = 0.027$ ), thus, we determined whether Fbxw7 was involved in invasion and metastasis in HCC. We first examined the mRNA levels of Fbxw7 in different HCC cell lines (i.e., HepG2, SMMC-7721 and MHCC97H) compared with the human liver non-tumor cell line HL-7702. As shown in Fig. 3A, the mRNA levels of Fbxw7 were significantly downregulated in HCC cells compared with HL-7702 cells. The western blot analysis also showed that the expression levels of Fbxw7 protein exhibited similar decreased tendencies in these HCC cell lines (Fig. 3B). Our previous study demonstrated that the invasion and metastasis capacity of HepG2 cells was the lowest, and the capacity of SMMC-7721 cells was moderate, whereas the capacity of MHCC97H cells was the greatest (32). In the present study, with the increase in invasive and metastatic potential in these three HCC cell lines, the mRNA and protein levels of Fbxw7 were downregulated.

*Lentivirus can efficiently change Fbxw7 expression in HCC cell lines.* Next, lentiviruses were used to change Fbxw7 expression in HCC cells. In order to facilitate the implementation of the experiment and accurately reflect the role of Fbxw7 in HCC cells, we chose HepG2 and MHCC97H cells for the subsequent experiments. We decided to downregulate the expression of Fbxw7 in HepG2 cell line (relatively high expression of Fbxw7) and upregulate the expression of Fbxw7 in MHCC97H cell line (relatively low expression of Fbxw7). We established lentivirus-mediated stable KD-Fbxw7-G2 and OE-Fbxw7-97H cells, and their respective negative controls

Table III. Univariate and multivariate Cox regression analyses of overall survival in 102 HCC patients.

Tumor characteristics	RR (95% CI)	P-value	Wald
<b>Univariate analysis</b>			
Fbxw7 (low/high)	0.384 (0.233-0.630)	<0.001 <sup>a</sup>	14.310
Gender (female/male)	1.112 (0.684-1.808)	0.667	0.185
Age (<50/≥50 years)	0.892 (0.543-1.467)	0.653	0.202
Liver cirrhosis (absence/presence)	1.036 (0.618-1.737)	0.894	0.018
Tumor number (single/multiple)	1.380 (0.861-2.213)	0.181	1.789
Tumor size (≤5/>5 cm)	0.683 (0.359-1.298)	0.244	1.357
Differentiation (high/low)	1.935 (1.093-3.425)	0.024 <sup>a</sup>	5.130
AFP (≥400/<400)	1.426 (0.893-2.277)	0.138	2.204
Venous invasion (-/+)	0.334 (0.150-0.745)	0.007 <sup>a</sup>	7.172
Metastasis (-/+)	0.200 (0.087-0.461)	<0.001 <sup>a</sup>	14.314
AJCC staging (I, II/III, IV)	0.377 (0.169-0.844)	0.018 <sup>a</sup>	5.628
<b>Multivariate analysis</b>			
Fbxw7 (low/high)	0.377 (0.232-0.613)	<0.001 <sup>a</sup>	15.454
Differentiation (high/low)	1.985 (1.161-3.394)	0.012 <sup>a</sup>	6.272
Venous invasion (-/+)	0.365 (0.180-0.743)	0.005 <sup>a</sup>	7.734
Metastasis (-/+)	0.236 (0.108-0.518)	<0.001 <sup>a</sup>	12.976
AJCC staging (I, II/III, IV)	0.321 (0.175-0.591)	<0.001 <sup>a</sup>	13.330

RR, relative risk; CI, confidence interval. <sup>a</sup>Statistically significant difference.




Figure 3. The expression levels of Fbxw7 is reduced in HCC cell lines. (A) qRT-PCR and western blot analysis of the Fbxw7 mRNA and protein expression levels in three HCC cells (HepG2, SMMC-7721 and MHCC97H) compared with the normal liver cell line HL-7702 and western blot analysis (B). For A, data are normalized to GAPDH and presented as the mean  $\pm$  SD; \* $P$ <0.05. For B, the expression of Fbxw7 protein was normalized to  $\beta$ -actin.

(i.e., NC-Fbxw7-G2 and NC-Fbxw7-97H cells). As Fig. 4A and C show, the state of HepG2 and MHCC97H cells after lentiviruses transfection is very good, and the efficiency is rather high based on the fluorescence images (at least 90%). qRT-PCR analysis showed that the expression of Fbxw7 in KD-Fbxw7-G2 cells decreased compared with NC-Fbxw7-G2 cells, whereas its level was constant in NC-Fbxw7-G2 cells vs. untransfected HepG2 cells (Fig. 4A). The expression of Fbxw7 in OE-Fbxw7-97H cells increased compared with NC-Fbxw7-97H cells, whereas its level was constant in NC-Fbxw7-97H cells vs. untransfected MHCC97H cells (Fig. 4C). The results suggested that lentivirus infection was highly efficient and did not perturb endogenous Fbxw7 expression in HCC cells. The western blot result also showed

that the expression levels of Fbxw7 protein was efficiently downregulated in KD-Fbxw7-G2 cells and upregulated in OE-Fbxw7-97H cells (Fig. 4B and D).

*Changes of Fbxw7 by lentivirus affects the migration and invasion of HCC cells.* Using the Transwell cell culture chambers, we measured the migration and invasion of Fbxw7 lentivirus-infected cells in HepG2 and MHCC97H cell lines. As illustrated in Fig. 5A and B, the number of KD-Fbxw7-G2 cells that migrated through the Transwell was significantly more than the number of NC-Fbxw7-G2 cells which migrated. In addition, the number of OE-Fbxw7-97H cells that migrated through the Transwell was significantly less than the number of NC-Fbxw7-97H cells which migrated




Figure 4. Lentiviruses can effectively change the expression of Fbxw7 mRNA and protein levels in HCC cells. qRT-PCR and western blot analysis of the mRNA and protein expression of downregulating Fbxw7 in HepG2 (A and B) and upregulating Fbxw7 in MHCC97H cells (C and D). The expression of Fbxw7 mRNA was normalized to GAPDH. The data are presented as the mean  $\pm$  SD; \* $P$ <0.05 compared with NT cells; # $P$ <0.05 compared with NT cells. NT, no transfection; NC, negative controls; KD, knock-down Fbxw7 levels with lentivirus; OE, overexpress Fbxw7 levels with lentivirus; KD-G2/OE-97H-B, bright-field microscopic image; KD-G2/OE-97H-F, fluorescence microscopic image. Original magnification,  $\times 200$ .

(Fig. 5E-F). We performed the invasion experiments, and the results agreed with the results of migration experiments (Fig. 5A, C, E and G). To confirm that the inhibitory effects of regulated Fbxw7 on cell migration and invasion were independent of apoptosis, an MTT assay was used to detect KD-Fbxw7-G2 and OE-Fbxw7-97H cells. According to the results of the MTT assay, Fbxw7 had no significant effects on the viability of MHCC97H and HepG2 cells (Fig. 5D and H). Thus, these data indicated that the migration and invasion capacity of HCC cells were reduced by the overexpression of Fbxw7, and the migration and invasion capacity were increased by the knockdown of Fbxw7.

*Notch1 and its downstream molecules MMP-2, MMP-9 and uPA are regulated by Fbxw7.* In order to confirm our speculation, we examined constitutively active Notch1 (i.e., the intracellular domain of Notch1, N1-ICD) protein levels in lentivirus-transfected cells. As shown in Fig. 6A, after the lentivirus infection of HCC cells, N1-ICD expression was negatively changed compared with Fbxw7. This result indicated that upregulation of Fbxw7 decreases the protein expression of N1-ICD in HCC cells or vice versa, serving as the basis of the remaining experiments. Furthermore, to determine the potential mechanisms of Fbxw7 in the migration and invasion of HCC cells, we examined the effect of changed Fbxw7 on metastasis-associated molecules, such as MMP-2, MMP-9 and uPA which were also downstream targets of Notch1. As Fig. 6B shows, downregulation of Fbxw7

increased the protein expression of MMP-2, MMP-9 and uPA in HepG2 cells and upregulation of Fbxw7 decreased their protein expression in MHCC97H cells. As we had designed the siRNA targeting Notch1 mRNA (siNotch1) in previous experiments. We decided to use KD-Fbxw7-G2 cells in the remaining experiments. We examined whether there is a negative feedback effect with Notch1 to Fbxw7. However, qRT-PCR analysis showed that Fbxw7 mRNA levels did not change significantly after the interference with siNotch1 in HepG2 cells (Fig. 6C), and the western blot analysis obtained similar results (Fig. 6D). We concluded that loss of Fbxw7 resulted in consistent accumulation of the intracellular domain of Notch1, implicating Notch1 as a relevant substrate of Fbxw7 in HCC.

*siNotch1 decreases the enhanced migration and invasion caused by the downregulation of Fbxw7 in HepG2 cells.* To confirm whether inhibiting Notch1 can offset the migration and invasion capacity which have been changed by Fbxw7 in HepG2 cells. We used the Transwell cell culture chambers again to measure the migration and invasion of KD-Fbxw7-G2 cells under the interference with siNotch1. As illustrated in Fig. 7, the number of KD-Fbxw7-G2 cells that migrated was significantly more than the number of NC-Fbxw7-G2 cells migrated. However, siNotch1 decreased the number of KD-Fbxw7-G2 cells migrated and make the cell numbers almost returned to the level of the untransfected cells. The results of invasion were the same as for the




Figure 5. Downregulation of Fbxw7 increases the migration and invasion of HepG2 and upregulation of Fbxw7 decreases the migration and invasion of MHCC97H cells *in vitro*. (A-C) Migrated and invaded KD-Fbxw7-G2 analyzed by Transwell assays compared with NC-Fbxw7-G2 cells. (E-G) Migrated and invaded OE-Fbxw7-97H analyzed by Transwell assays compared with NC-Fbxw7-97H cells. (D and H) MTT analysis of the cell viability of lentivirus-treated HepG2 and MHCC97H cells. The data are presented as the mean  $\pm$  SD, \* $P$ <0.05 compared with NT-HepG2 cells; # $P$ <0.05 compared with NT-MHCC97H cells. NT, no transfection; NC, negative controls; KD, knock-down Fbxw7 levels with lentivirus; OE, overexpress Fbxw7 levels with lentivirus.

migration. These results indicated that Notch1 cannot affect Fbxw7 in a negative feedback mechanism. However, Notch1 can offset the migration and invasion capacity changed by Fbxw7 in HCC cells.

## Discussion

Hepatocellular carcinoma (HCC) is one of the most common human malignancies and also the leading cause of cancer-related death in the world. The mechanisms underlying the progression and metastasis of HCC remain unclear. As a well-known tumor suppressor, both Fbxw7 mRNA and protein expression levels were significantly reduced in gastric, colorectal cancer, melanoma, glioma and HCC (22,33-36). Loss-of-function mutations of Fbxw7 were frequently found in various types of cancers as described in the Introduction of the present study. A functional study found that Fbxw7-deficient cerebella of mice showed aberrant progenitor cell migration (37). Another study showed that, gastric cancer patients with lymph node metastasis showed reduced Fbxw7

levels compared with patient-matched normal gastric mucosa (21). In addition, the findings of Cheng *et al* (22) indicated that Fbxw7 inhibits melanoma cell migration and may serve as a prognostic marker. In the present study, we sought to determine the role of Fbxw7 in HCC cell migration and invasion. Initially, we used immunohistochemistry to observe the expression of Fbxw7 in HCC tissues. Combining with the clinicopathological characteristics, the results showed that low levels of Fbxw7 expressions in tumor tissues were significantly correlated with tumor differentiation ( $P=0.013$ ), venous invasion ( $P=0.031$ ), metastasis ( $P=0.027$ ) and AJCC cancer stage ( $P=0.047$ ). These clinical indicators also represent the performance of advanced tumor. The results strongly suggested that Fbxw7 may play key roles in the progression of HCC. Whether Fbxw7 can be used as a prognostic molecular biomarker to guide clinical work is of concern to clinicians. The Kaplan-Meier analysis of the survival curves showed a significantly better overall survival rate for patients with high Fbxw7 expression levels (log-rank test,  $P<0.001$ ), indicating that low Fbxw7 protein levels is a marker of poor prognosis




Figure 6. Fbxw7 regulates the expression of Notch1 and its downstream molecules in HCC cells. (A) The protein expression of N1-ICD was measured by western blot analysis in KD-Fbxw7-G2 and OE-Fbxw7-97H cells. (B) The protein expression of MMP-2, MMP-9, and uPA was measured by western blot analysis in KD-Fbxw7-G2 and OE-Fbxw7-97H cells. (C) qRT-PCR analysis of Notch1 and Fbxw7 mRNA levels in HepG2 cells which were treated with siNotch1 and siControl compared with NT cells. (D) Western blot analysis of Notch1 and Fbxw7 protein expression in HepG2 cells which were treated with siNotch1 and siControl compared with NT cells. The data are presented as the mean  $\pm$  SD, \* $P < 0.05$  compared with NT cells. NT, no transfection; NC, negative controls; KD, knock-down Fbxw7 levels with lentivirus; OE, overexpress Fbxw7 levels with lentivirus; SC, siControl (control siRNA transfection); SN, siNotch1 (Notch1 siRNA transfection).

for patients with HCC. Moreover, a multivariate Cox regression analyses demonstrated that low Fbxw7 expression was correlated with worse outcomes and might be an independent predictor for patients with HCC. Thus, expression of Fbxw7 could constitute a useful additive prognostic factor to the AJCC staging system for HCC patients who are more likely to have tumor recurrence and should receive aggressive adjuvant chemotherapeutic treatment. The most significant finding from analysis of clinicopathological characteristics is the correlation between Fbxw7 levels with the vascular invasion and metastasis of HCC. This finding suggests Fbxw7 may have relevance with the migration and invasion of HCC cells. However, no study has been conducted on this function of Fbxw7 and its mechanism in the regulation of the migration and invasion in HCC cells. Our previous

study also demonstrated that the expression levels of Notch1 mRNA and protein exhibited similar increased tendencies related to invasion capability (32). In addition, Notch1 is a well-acknowledged target of Fbxw7. Therefore, we focused on Notch1 and speculate that Fbxw7 regulates Notch1, and then changes the invasive and metastatic ability of HCC cells.

Notch signaling pathway controls a variety of processes, involving cellular differentiation, proliferation and apoptotic events at all stages of development (38). Notch (Notch1-4) are trans-membrane proteins, which interact with ligands of the Delta-like (DLL-1, 3 and 4) and Jagged (Jagged1 and 2) family. Binding of ligand to its receptor induces metalloproteinase-mediated and  $\gamma$ -secretase-mediated cleavage of the Notch receptor (39). Thereby the Notch1 intracellular domain (N1-ICD) was generated and released from the




Figure 7. Downregulation of Notch1 decreases the enhanced migration and invasion caused by the downregulation of Fbxw7 in HepG2 cells *in vitro*. (A-C) Migrated and invaded KD-Fbxw7-G2 was analyzed by Transwell assays compared with the cells further treated with siControl and siNotch1. (D) MTT analysis of the cell viability of lentivirus-treated HepG2 and siRNA-transfected HepG2 cells. The data are presented as the mean  $\pm$  SD, \* $P < 0.05$  compared with KD-Fbxw7-G2 cells. NC, negative controls; KD, knock-down Fbxw7 levels with lentivirus; KD+SC, KD-Fbxw7-G2 cells further treated with control siRNA transfection; KD+SN, KD-Fbxw7-G2 cells further treated with Notch1 siRNA transfection.

membrane (40). Then N1-ICD is translocated into the nucleus and finally degraded by the ubiquitin-proteasome system with the aid of Fbxw7 (41-43). A number of studies have confirmed that Notch1 is mainly upregulated in the brain (44), gastric cancer (45), colorectal cancer, leukemia, ovarian cancer and HCC (29). In contrast, Notch1 has also been shown to be downregulated in lung (46), breast (47), prostate, kidney cancer and myeloma (48). It has been shown that Notch1 is involved in tumor cell invasion in pancreatic, breast cancer, lingual squamous cell carcinoma and HCC (25-28). Additionally, high Notch1 expression has been reported to be related to poor overall survival rates in colorectal, breast cancer and HCC (49,50). Latest studies proved that Notch1, as the substrate of Fbxw7 which can inhibit melanoma cell migration, was activated to promote melanoma angiogenesis and tumor growth through Fbxw7 silencing (30). However, whether Fbxw7/Notch1 axis participates in the process of metastasis and invasion in HCC remains unclear. In the present study, upregulated Fbxw7 decreased the protein expression of activated Notch1 in MHCC97H cells and downregulated Fbxw7 increased activated Notch1 levels in

HepG2 cells. However, Fbxw7 protein levels did not change significantly with the inhibition of siNotch1. These results indicated that Notch1 was the substrate of Fbxw7 in HCC and Fbxw7/Notch1 participated in the HCC progression and metastasis.

The metastasis of tumor is a multi-step biochemical reaction with many molecular events. The degradation of matrix proteins is an essential step of local invasion and metastasis, while the matrix metalloproteinases (MMPs) are the most important proteolytic enzymes involved by the tumor invasion and metastasis. MMPs are a family of related enzymes that degrade the basement membrane and the extracellular matrix (ECM). The activation of these enzymes promotes tumor cells accessing vasculature, and then the target organs, forming tumor metastasis (51). Studies have also found that, MMPs are able to promote the release of growth factors to stimulate tumor cell growth and movement to develop metastasis. At present, 23 members of the MMPs family are known in humans (52). Most researchers have focused on the MMP-2 and MMP-9, the gelatinases which are able to degrade type IV collagen (53-56). Type IV collagen is the principal component

of basement membranes separating the epithelial cells from the underlying stroma (57). In addition to the presence of MMPs, urokinase-type plasminogen activator (uPA) system is also essential for the degradation of ECM. uPA can facilitate the conversion of plasminogen to plasmin. Activation of uPA, which is dependent on the binding of pro-uPA (prourokinase) to uPAR (uPA receptor) (58), can be achieved by plasmin (59), creating a feedback loop by which plasmin and uPA can activate each other (60). The activated plasmin, directly or indirectly through MMPs, degrade ECM, laminin, fibronectin, type IV collagen and other components of the basement membrane, contributing to cancer cell invasion and metastases (61). In the present study, Fbxw7 showed its ability to regulate the migration and invasion of HCC cells. Downregulated Fbxw7 can increase the migration and invasion of HCC cells involved with the increased expression of Notch1, MMP2, MMP9 and uPA. Our previous studies demonstrated that MMP-2, MMP-9 and uPA were downstream targets of Notch1 in HCC cells. In this respect, the potential mechanism may be that down-regulating Fbxw7 increases the migration and invasion of HCC cells via upregulating Notch1 which activates MMP-2, MMP-9 and uPA.

Our previous studies confirmed that MMP-2, MMP-9 and uPA were regulated by Notch1 via the ERK1/2 signal pathway. In addition, Cheng *et al* (22) reported that Fbxw7 inhibits melanoma cell migration through the MAPK/ERK signaling pathway. Therefore, we consider this is also the mechanism of Fbxw7 influencing the migration and invasion of HCC cells. ERK1/2, which contains two isoforms: p44 (ERK1) and p42 (ERK2), is a well-studied subfamily of MAPKs (62). The activated ERK1/2 pathway acts on a variety of transcription factors and nuclear proteins, promotes transcription and expression of certain genes, involved in multiple biological effects such as tumor cell proliferation, differentiation, migration, invasion and apoptosis. It has been reported that the MAPK/ERK pathway inhibitors could be used to inhibit the migration of numerous cell types in response to cell matrix, such as growth factors, fibronectin, vitronectin, collagen and other stimuli (63-66). Certain metastasis-related genes such as MMP-2, MMP-9 and uPA are regulated by activated ERK1/2. It was reported that Fbxw7 inhibits melanoma cell migration through the MAPK/ERK signaling pathway (67,68). Combined with our experimental results *in vitro*, we therefore propose that the Fbxw7/Notch1/ERK axis may provide a potential approach for suppression of HCC metastasis.

In summary, our findings clearly demonstrate that low levels of Fbxw7 expression is significantly correlated with HCC progression and poor prognosis through clinicopathological analysis. Therefore, Fbxw7 expression can be used as an additional indicator to improve prognostication for survival of patients with HCC. Furthermore, we propose that Fbxw7 may regulate Notch1 via interacting with ERK1/2 signal pathways related to HCC metastasis. Therefore, based on the experiments *in vitro* with migration and invasion of HCC cells, we hypothesize that targeting Fbxw7 may be useful for devising novel preventive and therapeutic strategies for HCC. However, the function of Fbxw7 involvement in HCC is far beyond that already known, therefore, more of its mechanisms should be explored.

## References

- Farazi PA and DePinho RA: Hepatocellular carcinoma pathogenesis: From genes to environment. *Nat Rev Cancer* 6: 674-687, 2006.
- Villanueva A, Savic R and Llovet JM: Lymphotoxins: New targets for hepatocellular carcinoma. *Cancer Cell* 16: 272-273, 2009.
- Wang Z, Inuzuka H, Fukushima H, Wan L, Gao D, Shaik S, Sarkar FH and Wei W: Emerging roles of the FBW7 tumour suppressor in stem cell differentiation. *EMBO Rep* 13: 36-43, 2012.
- Welcker M and Clurman BE: FBW7 ubiquitin ligase: A tumour suppressor at the crossroads of cell division, growth and differentiation. *Nat Rev Cancer* 8: 83-93, 2008.
- Wang Z, Inuzuka H, Zhong J, Wan L, Fukushima H, Sarkar FH and Wei W: Tumor suppressor functions of FBW7 in cancer development and progression. *FEBS Lett* 586: 1409-1418, 2012.
- Koepp DM, Schaefer LK, Ye X, Keyomarsi K, Chu C, Harper JW and Elledge SJ: Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. *Science* 294: 173-177, 2001.
- Welcker M, Orian A, Jin J, Grim JE, Harper JW, Eisenman RN and Clurman BE: The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. *Proc Natl Acad Sci USA* 101: 9085-9090, 2004.
- Wu G, Lyapina S, Das I, Li J, Gurney M, Pauley A, Chui I, Deshaies RJ and Kitajewski J: SEL-10 is an inhibitor of notch signaling that targets notch for ubiquitin-mediated protein degradation. *Mol Cell Biol* 21: 7403-7415, 2001.
- Tu K, Zheng X, Yin G, Zan X, Yao Y and Liu Q: Evaluation of Fbxw7 expression and its correlation with expression of SREBP-1 in a mouse model of NAFLD. *Mol Med Rep* 6: 525-530, 2012.
- Nateri AS, Riera-Sans L, Da Costa C and Behrens A: The ubiquitin ligase SCFFbw7 antagonizes apoptotic JNK signaling. *Science* 303: 1374-1378, 2004.
- Mao JH, Kim IJ, Wu D, Climent J, Kang HC, Del Rosario R and Balmain A: FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. *Science* 321: 1499-1502, 2008.
- Inuzuka H, Shaik S, Onoyama I, Gao D, Tseng A, Maser RS, Zhai B, Wan L, Gutierrez A, Lau AW, *et al*: SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. *Nature* 471: 104-109, 2011.
- Cheng Y and Li G: Role of the ubiquitin ligase Fbw7 in cancer progression. *Cancer Metastasis Rev* 31: 75-87, 2012.
- Akhoodi S, Sun D, von der Lehr N, Apostolidou S, Klotz K, Maljukova A, Cepeda D, Fiegl H, Dafou D, Marth C, *et al*: FBXW7/hCDC4 is a general tumor suppressor in human cancer. *Cancer Res* 67: 9006-9012, 2007.
- Onoyama I, Suzuki A, Matsumoto A, Tomita K, Katagiri H, Oike Y, Nakayama K and Nakayama KI: Fbxw7 regulates lipid metabolism and cell fate decisions in the mouse liver. *J Clin Invest* 121: 342-354, 2011.
- Maser RS, Choudhury B, Campbell PJ, Feng B, Wong KK, Protopopov A, O'Neil J, Gutierrez A, Ivanova E, Perna I, *et al*: Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. *Nature* 447: 966-971, 2007.
- Lee JW, Soung YH, Kim HJ, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ and Lee SH: Mutational analysis of the hCDC4 gene in gastric carcinomas. *Eur J Cancer* 42: 2369-2373, 2006.
- Kemp Z, Rowan A, Chambers W, Wortham N, Halford S, Sieber O, Mortensen N, von Herbay A, Gunther T, Ilyas M, *et al*: CDC4 mutations occur in a subset of colorectal cancers but are not predicted to cause loss of function and are not associated with chromosomal instability. *Cancer Res* 65: 11361-11366, 2005.
- Hubalek MM, Widschwendter A, Erdel M, Gschwendtner A, Fiegl HM, Müller HM, Goebel G, Mueller-Holzner E, Marth C, Spruck CH, *et al*: Cyclin E dysregulation and chromosomal instability in endometrial cancer. *Oncogene* 23: 4187-4192, 2004.
- Koh MS, Ittmann M, Kadmon D, Thompson TC and Leach FS: CDC4 gene expression as potential biomarker for targeted therapy in prostate cancer. *Cancer Biol Ther* 5: 78-83, 2006.
- Li J, Guo Y, Liang X, Sun M, Wang G, De W and Wu W: MicroRNA-223 functions as an oncogene in human gastric cancer by targeting FBXW7/hCdc4. *J Cancer Res Clin Oncol* 138: 763-774, 2012.

22. Cheng Y, Chen G, Martinka M, Ho V and Li G: Prognostic significance of Fbw7 in human melanoma and its role in cell migration. *J Invest Dermatol* 133: 1794-1802, 2013.
23. Imura S, Tovuu LO, Utsunomiya T, Morine Y, Ikemoto T, Arakawa Y, Kanamoto M, Iwahashi S, Saito Y, Takasu C, *et al*: The role of Fbxw7 expression in hepatocellular carcinoma and adjacent non-tumor liver tissue. *J Gastroenterol Hepatol* 29: 1822-1829, 2014.
24. Tu K, Zheng X, Zan X, Han S, Yao Y and Liu Q: Evaluation of Fbxw7 expression and its correlation with the expression of c-Myc, cyclin E and p53 in human hepatocellular carcinoma. *Hepatol Res* 42: 904-910, 2012.
25. Wang Z, Banerjee S, Li Y, Rahman KM, Zhang Y and Sarkar FH: Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. *Cancer Res* 66: 2778-2784, 2006.
26. Yu B, Wei J, Qian X, Lei D, Ma Q and Liu Y: Notch1 signaling pathway participates in cancer invasion by regulating MMPs in lingual squamous cell carcinoma. *Oncol Rep* 27: 547-552, 2012.
27. Wang J, Fu L, Gu F and Ma Y: Notch1 is involved in migration and invasion of human breast cancer cells. *Oncol Rep* 26: 1295-1303, 2011.
28. Zhou L, Wang DS, Li QJ, Sun W, Zhang Y and Dou KF: Downregulation of the Notch signaling pathway inhibits hepatocellular carcinoma cell invasion by inactivation of matrix metalloproteinase-2 and -9 and vascular endothelial growth factor. *Oncol Rep* 28: 874-882, 2012.
29. Zhou L, Zhang N, Song W, You N, Li Q, Sun W, Zhang Y, Wang D and Dou K: The significance of Notch1 compared with Notch3 in high metastasis and poor overall survival in hepatocellular carcinoma. *PLoS One* 8: e57382, 2013.
30. Aydin IT, Melamed RD, Adams SJ, Castillo-Martin M, Demir A, Bryk D, Brunner G, Cordon-Cardo C, Osman I, Rabadan R, *et al*: FBXW7 mutations in melanoma and a new therapeutic paradigm. *J Natl Cancer Inst* 106: djul07, 2014.
31. Barnes DM, Harris WH, Smith P, Millis RR and Rubens RD: Immunohistochemical determination of oestrogen receptor: Comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. *Br J Cancer* 74: 1445-1451, 1996.
32. Zhou L, Zhang N, Li QJ, Sun W, Zhang Y, Wang DS and Dou KF: Associations between high levels of Notch1 expression and high invasion and poor overall survival in hepatocellular carcinoma. *Tumour Biol* 34: 543-553, 2013.
33. Yokobori T, Mimori K, Iwatsuki M, Ishii H, Onoyama I, Fukagawa T, Kuwano H, Nakayama KI and Mori M: p53-Altered FBXW7 expression determines poor prognosis in gastric cancer cases. *Cancer Res* 69: 3788-3794, 2009.
34. Iwatsuki M, Mimori K, Ishii H, Yokobori T, Takatsuno Y, Sato T, Toh H, Onoyama I, Nakayama KI, Baba H, *et al*: Loss of FBXW7, a cell cycle regulating gene, in colorectal cancer: Clinical significance. *Int J Cancer* 126: 1828-1837, 2010.
35. Hagedorn M, Delugin M, Abbraldes I, Allain N, Belaud-Rotureau MA, Turmo M, Prigent C, Loiseau H, Bikfalvi A and Javerzat S: FBXW7/hCDC4 controls glioma cell proliferation in vitro and is a prognostic marker for survival in glioblastoma patients. *Cell Div* 2: 9, 2007.
36. Zhou ZY, Tu KS, Zhang J, Zheng X, Gao J, Yao YM and Liu QG: Expression of Fbxw7 and its correlation with cell proliferation in human hepatocellular carcinoma. *Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi* 28: 1303-1306, 2012 (In Chinese).
37. Jandke A, Da Costa C, Sancho R, Nye E, Spencer-Dene B and Behrens A: The F-box protein Fbw7 is required for cerebellar development. *Dev Biol* 358: 201-212, 2011.
38. Artavanis-Tsakonas S, Rand MD and Lake RJ: Notch signaling: Cell fate control and signal integration in development. *Science* 284: 770-776, 1999.
39. Bedogni B, Warneke JA, Nickoloff BJ, Giaccia AJ and Powell MB: Notch1 is an effector of Akt and hypoxia in melanoma development. *J Clin Invest* 118: 3660-3670, 2008.
40. Blair SS: Notch signaling: Fringe really is a glycosyltransferase. *Curr Biol* 10: R608-R612, 2000.
41. Minella AC and Clurman BE: Mechanisms of tumor suppression by the SCF(Fbw7). *Cell Cycle* 4: 1356-1359, 2005.
42. Lai EC: Protein degradation: Four E3s for the notch pathway. *Curr Biol* 12: R74-R78, 2002.
43. Oberg C, Li J, Pauley A, Wolf E, Gurney M and Lendahl U: The Notch intracellular domain is ubiquitinated and negatively regulated by the mammalian Sel-10 homolog. *J Biol Chem* 276: 35847-35853, 2001.
44. Sun L, Hui AM, Su Q, Vortmeyer A, Kotliarov Y, Pastorino S, Passaniti A, Menon J, Walling J, Bailey R, *et al*: Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. *Cancer Cell* 9: 287-300, 2006.
45. D'Errico M, de Rinaldis E, Blasi MF, Viti V, Falchetti M, Calcagnile A, Sera F, Saieva C, Ottini L, Palli D, *et al*: Genome-wide expression profile of sporadic gastric cancers with microsatellite instability. *Eur J Cancer* 45: 461-469, 2009.
46. Landi MT, Dracheva T, Rotunno M, Figueroa JD, Liu H, Dasgupta A, Mann FE, Fukuoka J, Hames M, Bergen AW, *et al*: Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. *PLoS One* 3: e1651, 2008.
47. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, *et al*: METABRIC Group: The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature* 486: 346-352, 2012.
48. Su BH, Qu J, Song M, Huang XY, Hu XM, Xie J, Zhao Y, Ding LC, She L, Chen J, *et al*: NOTCH1 signaling contributes to cell growth, anti-apoptosis and metastasis in salivary adenoid cystic carcinoma. *Oncotarget* 5: 6885-6895, 2014.
49. Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, Lockwood G and Egan SE: High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. *Cancer Res* 65: 8530-8537, 2005.
50. Chu D, Li Y, Wang W, Zhao Q, Li J, Lu Y, Li M, Dong G, Zhang H, Xie H, *et al*: High level of Notch1 protein is associated with poor overall survival in colorectal cancer. *Ann Surg Oncol* 17: 1337-1342, 2010.
51. Itoh Y and Nagase H: Matrix metalloproteinases in cancer. *Essays Biochem* 38: 21-36, 2002.
52. Nagase H, Visse R and Murphy G: Structure and function of matrix metalloproteinases and TIMPs. *Cardiovasc Res* 69: 562-573, 2006.
53. Kato Y, Yamashita T and Ishikawa M: Relationship between expression of matrix metalloproteinase-2 and matrix metalloproteinase-9 and invasion ability of cervical cancer cells. *Oncol Rep* 9: 565-569, 2002.
54. Giambernardi TA, Grant GM, Taylor GP, Hay RJ, Maher VM, McCormick JJ and Klebe RJ: Overview of matrix metalloproteinase expression in cultured human cells. *Matrix Biol* 16: 483-496, 1998.
55. Iwasaki M, Nishikawa A, Fujimoto T, Akutagawa N, Manase K, Endo T, Yoshida K, Maekawa R, Yoshioka T and Kudo R: Anti-invasive effect of MMI-166, a new selective matrix metalloproteinase inhibitor, in cervical carcinoma cell lines. *Gynecol Oncol* 85: 103-107, 2002.
56. Komatsu K, Nakanishi Y, Nemoto N, Hori T, Sawada T and Kobayashi M: Expression and quantitative analysis of matrix metalloproteinase-2 and -9 in human gliomas. *Brain Tumor Pathol* 21: 105-112, 2004.
57. Köhrmann A, Kammerer U, Kapp M, Dietl J and Anacker J: Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature. *BMC Cancer* 9: 188, 2009.
58. Behrendt N, Rønne E and Danø K: The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface. *Biol Chem Hoppe Seyler* 376: 269-279, 1995.
59. Skrzydlewska E, Sulkowska M, Koda M and Sulkowski S: Proteolytic-antiproteolytic balance and its regulation in carcinogenesis. *World J Gastroenterol* 11: 1251-1266, 2005.
60. Mason SD and Joyce JA: Proteolytic networks in cancer. *Trends Cell Biol* 21: 228-237, 2011.
61. Shimizu M, Cohen B, Goldvasser P, Berman H, Virtanen C and Reedijk M: Plasminogen activator uPA is a direct transcriptional target of the JAG1-Notch receptor signaling pathway in breast cancer. *Cancer Res* 71: 277-286, 2011.
62. Huang C, Jacobson K and Schaller MD: MAP kinases and cell migration. *J Cell Sci* 117: 4619-4628, 2004.

63. Anand-Apte B, Zetter BR, Viswanathan A, Qiu RG, Chen J, Ruggieri R and Symons M: Platelet-derived growth factor and fibronectin-stimulated migration are differentially regulated by the Rac and extracellular signal-regulated kinase pathways. *J Biol Chem* 272: 30688-30692, 1997.
64. Duncia JV, Santella JB III, Higley CA, Pitts WJ, Wityak J, Frieze WE, Rankin FW, Sun JH, Earl RA, Tabaka AC, *et al*: MEK inhibitors: The chemistry and biological activity of U0126, its analogs, and cyclization products. *Bioorg Med Chem Lett* 8: 2839-2844, 1998.
65. Webb DJ, Nguyen DH and Gonias SL: Extracellular signal-regulated kinase functions in the urokinase receptor-dependent pathway by which neutralization of low density lipoprotein receptor-related protein promotes fibrosarcoma cell migration and matrigel invasion. *J Cell Sci* 113: 123-134, 2000.
66. Klemke RL, Cai S, Giannini AL, Gallagher PJ, de Lanerolle P and Cheresch DA: Regulation of cell motility by mitogen-activated protein kinase. *J Cell Biol* 137: 481-492, 1997.
67. Cheng YC, Chen LM, Chang MH, Chen WK, Tsai FJ, Tsai CH, Lai TY, Kuo WW, Huang CY and Liu CJ: Lipopolysaccharide upregulates uPA, MMP-2 and MMP-9 via ERK1/2 signaling in H9c2 cardiomyoblast cells. *Mol Cell Biochem* 325: 15-23, 2009.
68. Arai K, Lee SR and Lo EH: Essential role for ERK mitogen-activated protein kinase in matrix metalloproteinase-9 regulation in rat cortical astrocytes. *Glia* 43: 254-264, 2003.

RETRACTED